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  Major depressive disorder (MDD) afﬂ  icts  an  esti-
mated 16% to 20% of the population during their life-
time [1  –  3]. In Australia 3.1% of men and 5.1% of 
women are affected in any 12-month period [4]. Current 
treatments include pharmacological, psychological and 
physical therapies. Antidepressants are amongst the 
most commonly prescribed classes of drugs [5] and their 
use continues to grow [6]. Adverse outcomes are part of 
the landscape in prescribing medications and therefore 
management of safety issues need to be an integral part 
of practice. 
  The adverse effects of antidepressants vary between 
individual drugs and drug classes and have been exten-
sively documented [7  –  9]. In general tricyclic antidepres-
sants (TCAs) and monoamine oxidase inhibitors 
(MAOIs) are associated with more severe adverse effect 
proﬁ  les than the newer antidepressants. MAOIs interact 
with dietary tyramine necessitating patient counselling 
about dietary risks [10]. While there is substantial intra-
variation in tolerability, MAOIs and TCAs retain an 
important place in the management of refractory depres-
sion [10] and the more putatively biological depressive 
disorders such as melancholia [11]. The selective 
  serotonin reuptake inhibitors (SSRIs) and selective sero-
tonin and noradrenaline reuptake inhibitors (SNRIs) 
broadly have lower toxicity than older agents [12], but 
have also been associated with signiﬁ  cant adverse effects 
including cardiovascular effects, sexual dysfunction [8], 
weight gain [13], electrolyte disturbances, haematologi-
cal effects [8] and hepatic damage [14]. A possible 
increase in suicidal thoughts and self-destructive behav-
iour in paediatric patients prescribed antidepressants has 
been documented [15] and regulatory warnings have 
been extended for young people up to the age of 25 years 
[16]. Most treatment guidelines recommend clinician 
vigilance for adverse symptoms or caution when admin-
istering antidepressants to people from high risk popula-
tions, including those with a prior history of medication 
sensitivity, the medically unwell [17], the elderly [18], 
adolescents [19] and pregnant or breastfeeding women 
[20]. Speciﬁ  c recommendations are, however, not widely 
available. 
  MDD is frequently comorbid with physical problems 
and illnesses including obesity [21], cardiovascular dis-
ease and diabetes mellitus [22], substance misuse and 
other mental disorders, reﬂ  ecting both antecedent and 
consequence pathways [23]. This may affect the efﬁ  cacy 
of treatments for MDD as well as increasing the vulner-
ability of patients to adverse effects and risk of harmful 
drug interactions. 
  Non-pharmacological treatments for MDD including 
psychotherapy [24] have also been associated with 
adverse events. Such adverse effects are, however, less 
frequently reported. Complementary and alternative 
treatments can be associated with adverse events [25] 
and pharmacological interactions. Even exercise, which 
has an established evidence base in depression treat-
ment [26], may be associated with adverse effects in 
individuals with comorbid cardiovascular disease, pro-
longed QT interval or who attempt strenuous activity 
without a period of adjustment [27]. However, gradual 
exercise training for rehabilitation following a major 
cardiac event in depressed individuals is associated 
with 73% reduced mortality when compared to 
depressed individuals who did not participate in exer-
cise training [28]. 
  Guidelines exist for safety monitoring of treatments 
for schizophrenia [29], bipolar disorder [30] and for spe-
ciﬁ  c medications (e.g. clozapine) [31], but there are none 
for clinical depression. Previous Australian guidelines 
focus on treatment algorithms [32]. Guidelines for base-
line screening and safety monitoring of antidepressant 
treatments may signiﬁ   cantly reduce risks of adverse 
events.  
  Method 
  Data were sourced by a literature search using MED-
LINE and a manual search of scientiﬁ  c journals to iden-
tify relevant articles. Searches were conducted on 
multiple occasions by individual co-authors. Draft guide-
lines were prepared and serially revised in an iterative 
manner until all co-authors gave ﬁ  nal approval of con-
tent. The process was completed over an 18 month period 
in 2010 and 2011.   
  The decision to treat 
  The management of depression should include an 
appropriate diagnostic work up, especially to exclude 
organic or self-limiting determinants. A person  ’  s indi-
vidual risk, prior treatment history and therapeutic pref-
erences should be assessed prior to treatment selection. 
  Choice of treatment must carefully balance efﬁ  cacy, 
potential harms and patient preference, facilitating an 
informed choice for patients to treatment that best 
matches their presentation [33]. The following sections 
will address evidence-based pre-treatment screening and 
monitoring of treatment of depression and are shown in 
Table 1. Baseline screening and monitoring recommen-
dations for speciﬁ  c depression augmentation strategies 
(e.g. lithium [30], the atypical antipsychotics [29]) are 
reviewed extensively elsewhere and hence are not 
included below. Similarly, monitoring of psychological 
therapy is beyond the scope of this paper [24].     714    ANTIDEPRESSANT SAFETY GUIDELINES   
melancholic depression [48]. Subclinical and past thyroid 
dysfunction is a risk factor for depression and antidepres-
sant non-response [49]. Identiﬁ  cation of abnormal thy-
roid function in depressed patients should prompt 
correction of thyroid hormone levels (T3 and T4), and 
where necessary, referral to an endocrinologist for further 
investigation. Depressive symptoms may resolve with 
correction of thyroid hormone levels. However, for some 
patients depressive symptoms may persist and require 
additional  treatment.   
  Full blood examination (FBE) 
  Full blood examination (FBE) can identify anaemia, 
potential underlying infections and blood dyscrasias that 
may contribute to depressive symptoms. Anaemia can 
induce fatigue and may be misinterpreted as, or contrib-
ute to, depressive symptoms. Alterations in leucocytes 
may alert to the presence of an underlying infection or 
other pathological process (e.g. cancer).     
  Liver function tests 
  Diseases of the liver have been associated with depres-
sion [50], and some antidepressant treatments are associ-
ated with hepatotoxicity [14]. Impaired liver function at 
baseline should prompt further investigation to determine 
and treat any hepatic disease. High levels of GGT and 
AST may suggest comorbid alcohol abuse, especially if 
concurrent with an increased mean cell volume [51]. 
Intravenous drug use may result in hepatitis C and cause 
abnormal liver function tests (LFT).     
  Screening for viral and other infections 
  Viral infections including human immunodeﬁ  ciency 
virus (HIV) [52], hepatitis C [53], West Nile virus [54] 
and Epstein-Barr virus [55, 56] are associated with 
depression, albeit uncommonly. This may relate directly 
to the infection or be consequent to elevated levels of 
cytokines that may themselves be biomarkers of risk for 
depression [57]. Fatigue is common following acute 
infective illness [58] and may be mistakenly attributed as 
a depressive symptom. In addition, antiviral treatment, 
most notably PEGylated interferon, can cause episodes 
of depression [59]. Though uncommon in contemporary 
practice, non-viral infections such as syphilis [60] can 
also cause depressive symptoms. Fatigue and depressive 
symptoms may be a response to activation of the immune 
system [61], suggesting that broader associations between 
infections, treatments for infections and the manifesta-
tion of depressive symptoms may exist. Prior to com-
mencing antidepressants, a detailed history of past 
infectious illness and treatments should be acquired, and 
  Baseline screening prior to commencement 
of treatment   
  Patient history and physical examination 
  Obtaining a thorough patient history and examination 
prior to commencing treatment is important in order to 
(i) determine whether medical factors may be inﬂ  uencing 
the current presentation, (ii) determine and document any 
risk factors which may increase susceptibility to adverse 
outcomes, (iii) establish baseline measures of physical 
and mental health in order to monitor treatment efﬁ  cacy 
and safety, and (iv) clarify depressive type and assist 
treatment selection. 
 Speciﬁ  c medical history information that can impact 
on monitoring and inﬂ  uence outcome includes substance 
use (e.g. alcohol [34], tobacco [35,36] and prescribed and 
illicit drugs), physical activity [37,38], life events, diet 
[39,40] and chronic and medical illness [41] as well as 
family history, history of illness and treatment history 
[42]. Personal or family history of thyroid, cardiac and 
cerebrovascular disease, hypertension, dyslipidaemia 
and/or diabetes mellitus should alert clinicians to 
increased risks associated with antidepressant treatments, 
and guide targeted baseline assessments. 
  Although uncommon, organic causes of depressive 
symptoms should be considered and evaluated before 
treatment is initiated. Organic causes include metabolic 
disorders, some vitamin deﬁ  ciencies (e.g. vitamin D [43, 
44], folate, B12, magnesium [45], zinc [46]), chronic 
pain, sleep apnoea, cancer, cerebrovascular disease, neu-
rological disorders, traumatic brain injury, autoimmune 
disease (systemic lupus erythematosus), some infections 
(hepatitis and HIV) and endocrine disorders [47]. Thy-
roid disease is an occasional medical cause of depressive 
symptom onset or persistence whilst Cushing  ’  s and 
Addison  ’  s disease are rare causes [48].     
  Blood and serological testing 
  Some organic causes of depressive symptoms can be 
detected through routine blood screening. The following 
tests may have a role in baseline screening prior to anti-
depressant  treatment.   
  Thyroid stimulating hormone (TSH) 
and thyroid hormones 
  Hyperthyroidism and hypothyroidism can be associ-
ated with mood disorders. Symptoms of hyperthyroidism 
include dysphoria, anxiety, restlessness, emotional labil-
ity and impaired concentration. Symptoms of hypothy-
roidism include psychomotor retardation, decreased 
appetite, fatigue and lethargy, which when severe mimics       S. DODD, G. S. MALHI, J. TILLER ET AL. 715
or withdrawal can be confused with a mood disorder [65]. 
Furthermore, comorbid alcohol or substance abuse are 
associated with antidepressant treatment resistance and 
non-adherence [66]. Obtaining a detailed drug and alco-
hol history is essential in patients with depression, 
although clinicians should be cognisant of potential 
underreporting. Blood or urine screening may be useful 
in selective cases although such screening only identiﬁ  es 
substances present at the time of the test. Collateral infor-
mation from relatives and friends, as well as other health 
professionals is invaluable to fully explore substance and 
alcohol issues. Raised transaminases, elevated carbohy-
drate deﬁ  cient transferrin and increased mean cell volume 
are a clue as to the presence of alcohol abuse.    
  Screen for prescription medications 
  Several medications are known to induce depressive 
symptoms. Interferon and other immune active agents 
supplemented with serological testing and testing of 
inﬂ   ammatory markers (erythrocyte sedimentation rate 
(ESR) and C-reactive protein (CRP)) if current infection 
is  suspected.   
  Alcohol and illicit substance screen 
  Alcohol abuse or dependence are causal factors con-
tributing to depression [62]. Many other substances have 
also been associated with depression; however, the direc-
tion of causality has not been clearly determined. Smok-
ing can increase the risk of depression [35], through direct 
neurotransmitter mechanisms and via pharmacokinetic 
drug interactions (e.g. tar components inducing hepatic 
isoenzymes CYP1A1, CYP1A2 and possibly CYP2E1) 
and pharmacodynamic drug interactions with nicotine 
[63]. Depressive symptoms may also emerge with smok-
ing cessation [64]. Cannabis, amphetamine and cocaine 
use are also associated with depression, and intoxication 
      Table 1. Monitoring recommendations for patients treated for major depressive disorder     
  Monitoring parameter    Agent   Frequency   Comments 
Electrocardiogram for QT 
prolongation
Tricylic antidepressants Baseline, after initial dose 
titration and at dose changes
More caution is indicated in 
children and the elderly and 
at higher doses
Liver function test Agents with hepatic 
liability
At the start of treatment and at 
6, 12 and 24 weeks of 
treatment and when clinically 
indicated
Mandated for agomelatine, other 
agents as indicated
BMI and waist circumference Agents with known weight 
gain liability
Baseline
    At one month and at 6 month 
intervals
More caution with mirtazapine, 
mianserin, tricyclics and 
MAOIs
Vitamin D, B12, folate, zinc, 
magnesium
All antidepressants Baseline If indicated
Electrolytes for 
hyponatraemia
SSRIs, mirtazapine, 
SNRIs and TCAs
At baseline and after one month 
if clinically indicated in high 
risk groups, especially the 
elderly (     65  years)
More frequent monitoring in 
elderly or those with existing 
hyponatraemia, follow up 
testing of urine and serum 
osmolality
Full Blood Examination to 
detect neutropaenia and 
thrombocytopaenia
Mirtazapine and 
mianserin
If clinically indicated
Suicidality All antidepressants, 
    especially SSRIs in 
adolescents
Weekly in the fi  rst few weeks of 
treatment. More frequent 
monitoring may be required in 
more severely depressed or 
suicidal patients
Particular caution in adolescents
    Warn next of kin/carer and ask 
for their collateral monitor as 
well
Antidepressant side-effect 
monitoring or Checklist
All antidepressants At one month and with reviews
Bone mineral density SSRIs As clinically indicated in high risk 
groups
Blood pressure monitoring Venlafaxine, tricyclics and 
MAOIs
With venlafaxine, tricyclics and 
MAOIs; at baseline, and with 
signifi  cant dose increase and 
3-6 monthly after stabilization
Closer monitoring of MAOI  ’  s in 
fi  rst weeks (tolerance occurs)716    ANTIDEPRESSANT SAFETY GUIDELINES   
  Metabolic proﬁ  le, waist circumference 
and body mass index 
  Many antidepressants are associated with weight gain, 
but depression, particularly atypical depression, can 
cause weight gain independent of medication [21,96]. 
Metabolic syndrome is a cluster of risk factors which 
identify individuals at high risk for cardiovascular dis-
ease and type II diabetes mellitus [97]. The prevalence 
of metabolic syndrome in patients with current major 
depression was found to be 56% in a Finnish study [98] 
and 25% in a German study [99]. The relationship 
between depression and metabolic syndrome is bidirec-
tional, with the syndrome also predictive of increased 
risk for depression [100]. A study of depressed inpatients 
recommended baseline metabolic screening for all hos-
pitalized depressed patients and re-screening during 
remission [99]. 
  Baseline measurements of height, weight (to calculate 
body mass index) and waist circumference should be 
undertaken. Patients should be questioned about risk fac-
tors for metabolic syndrome including smoking, personal 
or family history of diabetes, while observational analy-
sis will also commonly suggest those at high risk or like-
lihood of the syndrome or its complications, such as 
sleep apnoea. Where appropriate, advice regarding smok-
ing cessation should be given. Guidelines for reviewing 
risk factors for metabolic syndrome during antidepres-
sant treatment are given in the section detailing ongoing 
monitoring.   
 Cardiovascular  disease 
  People with depression are at an increased risk of 
developing cardiovascular disease [101]. In addition, 
some antidepressants (in particular TCAs) have associ-
ated adverse cardiovascular effects, although most of the 
newer antidepressants demonstrate low cardiotoxicity. 
TCAs may affect cardiac conduction and should be used 
with caution in patients with pre-existing cardiac disor-
ders (especially in those with recent myocardial infarc-
tion and arrhythmias) [102]. Although rare, case reports 
of adverse cardiac events with newer antidepressants 
exist, including atrial ﬁ  brillation associated with ﬂ  uox-
etine treatment [102] and mild bradycardia with ﬂ  uox-
etine, ﬂ  uvoxamine and paroxetine [12]. Adverse cardiac 
events usually occur in patients with additional risk fac-
tors such as smoking [103]. An ECG is probably indi-
cated at baseline and after attainment of therapeutic 
dosage in individuals with clinical risk factors who have 
been prescribed agents that can alter the ECG, particu-
larly TCAs. Baseline monitoring of blood pressure and 
pulse is useful and particularly important if a MAOI 
or TCA is prescribed [104]. Venlafaxine can cause 
(previously mentioned) may be directly causative of 
depressive episodes [59]. Benzodiazepine use may be 
associated with depression [67]. Opiates are frequently 
utilized agents especially in the context of chronic pain. 
Depression and chronic pain are commonly comorbid 
and iterative, and it is possible that chronic opiate use 
has a noxious effect on mood [68,69]. Other potential 
mood modifying agents include some steroidal and other 
hormonal treatments [70,71], cardiovascular drugs, cho-
lesterol lowering agents, parkinsonian agents, antibiotic 
agents [72], antineoplastic agents [73], anticonvulsants 
[74], typical antipsychotics and analgesics [75  –  78]. If 
there is a temporal association of the onset of depression 
and the commencement of a medication, then an assump-
tion of causality is practicable.     
 Vitamin  D 
  A high prevalence of vitamin D insufﬁ  ciency is found 
in most western societies [79] particularly amongst the 
elderly [80  –  83]. Psychiatric cohorts appear to have even 
higher rates of Vitamin D insufﬁ  ciency [43], with 58% of 
inpatients in one study having vitamin D insufﬁ  ciency and 
11% showing deﬁ  ciency. Low levels of vitamin D, which 
are common in winter, may contribute to seasonal affective 
disorder (SAD) [84,85] and a higher likelihood of develop-
ing a depressed mood [86,87]. There are some data, albeit 
inconsistent, that vitamin D supplementation may prevent 
or improve depressive symptoms [88,89]. While a compre-
hensive picture of the role of vitamin D in depression is 
yet to emerge, the high yield from screening and the sim-
plicity of supplementation suggests that screening may be 
worthwhile. There is some evidence that folate, vitamin 
B12 magnesium and selenium, amongst other nutrients, 
are deﬁ   cient in some individuals with depression, and 
inconsistent data that supplementation may be of value 
[45,90  –  92]. The absence of quality data limits evidence-
based recommendations regarding screening, but this 
should be considered if indicated by history.      
  Cognitive neuropsychological testing 
  Depression often overlaps with dementia and mild 
cognitive impairment in elderly patients. Late onset 
depression may be a prodrome of cognitive decline [93] 
and depressive symptoms can be confused with demen-
tia [94]. In patients with late-onset depression, diag-
nostic work up may require formal assessment of 
cognitive impairment. Late onset vascular depression 
has been associated with brain small vessel disease 
demonstrated by hyperintensities on MRI scans [95]. 
Patients with consistent symptoms should be assessed 
for vascular risk factors such as smoking, hypertension 
and diabetes.           S. DODD, G. S. MALHI, J. TILLER ET AL. 717
experimental stage. Typically, the tests either probe 
for polymorphisms of genes involved in neurotrans-
mitter function or probe for polymorphisms of genes 
involved in drug metabolism [111]. Currently, the role 
of genotyping to predict antidepressant adverse effects 
remains unclear. While there is evidence that genotyp-
ing cytochrome P450 polymorphisms detects poor 
metabolisers and ultra-rapid metabolizers with some 
level of accuracy, their clinical utility in dose ﬁ  nding 
remains under investigation [112,113]. At present 
there is no evidence supporting the use of these genetic 
tests in routine clinical practice, particularly as there 
is no demonstrated relationship between blood con-
centrations of the SSRIs or other new antidepressants 
and clinical efﬁ  cacy. The role of blood-brain barrier 
pump polymorphisms is also being explored [114]. 
There is limited evidence that certain genotypes are 
associated with higher rates of emergent suicidality 
while receiving an antidepressant, but results remain 
mixed [115]. At this stage, routine genetic testing of 
patients commencing antidepressants does not appear 
to have sufﬁ  cient evidence to guide recommendations. 
In selected patients with a history of medication sen-
sitivity or resistance, there may be a limited place for 
CYP450 genotyping. Should robust evidence of pre-
dicting pharmacogenetic response, tolerability and 
safety associations emerge there may be a greater 
place for such genotyping in the future.     
 Neuroimaging 
  Neuroimaging has advanced substantially in the past 
three decades, with current technology permitting the 
assessment of neurochemical concentrations within 
the brain, more detailed appreciation of its structure 
and connections and an intriguing insight into its func-
tionality. However, a lack of a consensus as regards 
diagnostic criteria and clinical phenotype of depres-
sion has meant that the emergence of characteristic 
neuroimaging features that have the necessary sen-
sitivity and speciﬁ  city at an individual level is yet to 
occur [116]. The only exception to this may be the use 
of MRI in cases of late onset depression to conﬁ  rm 
the presence of underlying causative small vessel dis-
ease. Late onset depression may at times progress to 
  dementia, and MRI will provide a baseline for future 
assessments.   
  Screening for electroconvulsive therapy 
  In most jurisdictions, electroconvulsive therapy (ECT) 
is subject to speciﬁ  c legislative constraints and treatment 
needs to respect these limitations [117]. Patients should 
be assessed, including relevant investigations into their 
tachycardia and increased blood pressure, and this merits 
monitoring [105]. Postural hypotension is particularly 
common with the MAOIs early in the treatment course, 
although tolerance typically develops. Antidepressant 
treatment may cause changes in cardiac function that are 
not outside the clinically normal range [12], therefore 
baseline measurements will be required to detect these 
changes.   
  Twenty-four-hour urinary free cortisol 
  Hypercortisolaemia and hypocortisolaemia are both 
associated with depression, although patients typically 
present with different symptom clusters. Hypocortiso-
laemia may be more likely to be associated with   ‘  atyp-
ical ’  depression, with symptoms including hypoarousal, 
hypersomnia, hyperphagia, lethargy, pain, fatigue and 
relative apathy, whereas hypercortisolaemia may be 
associated with   ‘  typical  ’   symptoms such as hyper-
arousal, anxiety, insomnia and loss of appetite [106]. 
It is unclear whether hypothalamic-pituitary-adrenal 
(HPA) axis activation is causative of depression and 
consequently information about plasma cortisol is of 
limited clinical use. The exception is hypercortisolae-
mia associated with Cushing  ’  s syndrome, where 
depressive symptoms are common and may improve 
with treatment of the endocrine disorder [106]. Endo-
crine and cytokine dysfunction often co-occur [107], 
which may also inﬂ  uence mood disturbances. A cushin-
goid appearance, impaired glucose tolerance and elec-
trolyte disturbance may point to this diagnosis, and a 
24-h urinary free cortisol measurement prior to com-
mencing antidepressant therapy may be useful in this 
scenario.   
 Pregnancy  testing 
  Screening for pregnancy, including detailed history 
and consideration of a pregnancy test where indicated is 
important for women of childbearing age. Pregnancy can 
inﬂ  uence mood, especially when associated with psycho-
social stressors such as an absent partner or when the 
pregnancy is unplanned [108]. Pregnancy also raises 
issues of potential drug-induced teratogenicity; hence 
knowledge of pregnancy status is important for guiding 
treatment choices [20,109,110].     
 Genetic  testing 
  Pharmacogenetics (genotype associations to medi-
cation response and tolerability) is an emerging area 
of promise in the safer and more effective prescription 
of various medications. Some pharmacogenetic tests 
are commercially available while others are still at an 718    ANTIDEPRESSANT SAFETY GUIDELINES   
being overweight at baseline is associated with further 
weight increase with antidepressant exposure. Most studies 
have found no clear association between antidepressant-
induced weight gain and baseline measures [122]. In some 
cases antidepressant treatment may reduce weight and 
abdominal fat by decreasing anxiety and regulating dietary 
patterns [123]. A naturalistic study found that weight gain 
in the ﬁ  rst week of antidepressant treatment was a signiﬁ  -
cant predictor of sustained weight gain [13]. There is limited 
evidence that ethnicity may inﬂ  uence weight increases with 
antidepressant treatment [124]. Early detection of weight 
gain and intervention to prevent sustained weight gain may 
have signiﬁ  cant beneﬁ  ts. Monitoring of the metabolic pro-
ﬁ  le may be prudent at 3, 6 and 12 months, then yearly, in 
all patients, not just in patients who are obese or overweight. 
While TCAs, MAOIs, mianserin and mirtazapine are most 
associated with weight gain [121], problems may arise with 
other newer antidepressants. Paroxetine may be more likely 
to cause weight gain than other SSRIs, and bupropion may 
be less likely than the SSRIs [125]. Particular attention 
should be given to those patients receiving augmentation or 
combination pharmacotherapy, especially with atypical 
antipsychotics [126].    
 Cardiovascular  status 
  Cardiovascular status may need monitoring during anti-
depressant treatment. Electrocardiography (ECG) is recom-
mended for patients being treated with the older 
antidepressants, especially in those over 45 years of age and 
those with cardiovascular disorders [12]. ECG should be 
considered prior to initiation of a TCA, and at steady state, 
for monitoring the QTc interval and for development of 
arrhythmias [127]. It may also be considered prior to com-
mencing treatment with an SNRI in high-risk individuals. 
QT prolongation is a common ﬁ  nding in the elderly. It can 
lead to Torsades de Pointes (a re-entrant tachycardia), result-
ing in ventricular ﬁ  brillation and sudden cardiac death. It is 
possible that such outcomes are under-reported. TCAs are 
known to cause QT prolongation by autonomic effects and 
effect on rapid outward potassium currents, resulting in 
delayed repolarization. Patients who have already been 
treated with a class I antiarrhythmic agent (Na   channel 
blocking) [12] and those who metabolize tricyclics more 
slowly (cytochrome CYP2D6 poor metabolizer phenotype) 
may be at increased risk [128]. Electrolyte disturbances, 
which can be a consequence of some antidepressants, 
increase the risk of arrhythmias [129]. 
  SSRIs have also been rarely associated with cases of 
Torsades de Pointes. There were 20 such cases associated 
with ﬂ   uoxetine, with one fatality, reported by WHO 
adverse drug effect monitoring between 1983 and 1999 
[130]. Cases associated with SSRIs, however, remain 
general physical health prior to receiving ECT. Acutely 
ill patients should only receive ECT as an inpatient, at 
least until their condition stabilizes, as suicide risk may 
increase in the early phase of treatment [118]. Investiga-
tions should be tailored to the individual patient depend-
ing on their history, physical examination and diagnosis. 
Screening for ECT overlaps considerably with pre-anaes-
thetic screening and general recommendations in this 
document. 
  Uncontrolled hypertension and cerebral tumours are 
absolute contraindications to ECT. Blood pressure 
must be assessed. Cochlear implants are a contraindi-
cation, unless removed. Cardiac pacemakers are not a 
contraindication, but it is essential to know the under-
lying cardiac rhythm and to liaise with the patient  ’  s 
cardiologist on pacemaker management with ECT. 
Cardiologist opinion should also be sought with patients 
who have severe aortic stenosis. Anaesthetic monitor-
ing includes ECG, pO  2   and pCO  2  , and respiratory rate 
monitoring of pO  2   and pCO  2   as well as pulse, blood 
pressure, respirations, and conscious state are critical 
in the recovery area.     
 Biomarkers 
  An emerging research area is that of biomarkers in 
depression. New data suggest certain biomarkers, includ-
ing cytokines such as CRP [128] and leptin [129], may 
be indicative of risk of development of de-novo depres-
sion. Other biomarkers have demonstrated a cross-
sectional association with depression, such as measures 
of oxidative stress and neurotrophins [130]. These mark-
ers are currently of research interest only, and while pro-
visional evidence suggests potential roles they may shed 
light on clinical course and outcome [131], data are too 
preliminary to merit incorporation in routine clinical 
screening.    
  Ongoing monitoring during antidepressant 
treatment  
 Suicide 
  After initiating antidepressant treatment, patients 
should be monitored for suicide risk. A thorough review 
of suicide monitoring is beyond the scope of this review, 
however practice guideline are available elsewhere 
[119, 120].     
  Obesity and metabolic syndrome 
  Waist circumference and body mass index should be 
monitored, particularly in patients treated with antidepres-
sants associated with weight gain [121]. It is unclear whether       S. DODD, G. S. MALHI, J. TILLER ET AL. 719
  It does not appear that susceptibility to antidepressant-
induced hepatotoxicity can be predicted by LFT or ALT 
before commencing antidepressant treatment. Therefore 
these tests are not used as a baseline screen to monitor 
risk for developing   de-novo   hepatic injury in response to 
antidepressant exposure [134]. However, they may be 
useful for detecting pre-existing hepatic injury and for 
establishing a baseline for patients before commencing 
antidepressant treatment and are required before com-
mencing treatment with agomelatine. Antidepressant-
induced hepatotoxicity typically occurs within the ﬁ  rst 
few months of treatment. 
  Nefazodone has been withdrawn from the Australian 
market as a result of cases of fatal hepatotoxicity 
[150,151]. Elevations of serum transaminases are docu-
mented in clinical trials of agomelatine but these changes 
usually return to normal levels after discontinuation. The 
European Medicines Agency has recommended a liver 
function test for patients treated with agomelatine at the 
start of treatment and at 6, 12 and 24 weeks of treatment 
and when clinically indicated [152]. 
 Lucena   et al  . [134] state that hepatotoxicity is an 
uncommon and unpredictable idiosyncratic reaction, 
and that there is no evidence that routine monitoring 
reduces the rate of hepatotoxicity with antidepressants 
in general. 
After a hepatotoxic reaction, if an antidepressant 
rechallenge is indicated, monthly liver functions test for 
the ﬁ  rst 6 months of treatment, with discontinuation of 
treatment if ALT values exceed (by three times) the upper 
limit of the normal range, if bilirubin levels rise, or if 
signs or symptoms of liver dysfunction are present, are 
recommended by the authors. If an individual develops 
increased serum transaminases, tests should be repeated 
within 48 h. After discontinuation, monitoring can be 
continued to ensure that liver function returns to the nor-
mal range. Rechallenge should be considered with cau-
tion, and only after careful consideration of risks and 
beneﬁ  ts. Adverse reactions to an antidepressant rechal-
lenge are not uncommon [150] and sometimes a more 
severe antidepressant-induced hepatotoxic reaction may 
occur following antidepressant rechallenge [139,153].     
 Hyponatraemia 
  SSRIs and some other antidepressants have been 
reported to cause hyponatraemia. The incidence rate in 
the elderly is 4.7 cases/1000 people treated/year 
[154,155], but is much lower in younger age groups. It 
should be suspected if an elderly patient becomes 
confused or develops a frank delirium after commence-
ment of an antidepressant. It may be why a person  ’  s 
mood may inexplicably worsen. Deaths associated with 
infrequent, sporadic and often involve overdose or drug 
interactions. Overdose of tricyclics and SSRIs mimic the 
appearance of Brugada  ’  s syndrome with right bundle 
branch block and ST elevation [131], suggesting some 
drugs (including ﬂ  uoxetine and amitriptyline) may also 
block cardiac sodium channels. Baseline ECG is impor-
tant in excluding familial long QT syndrome and to 
reveal T or U wave abnormalities. Repeat ECG monitor-
ing of QT prolongation may be indicated when signiﬁ  -
cant dose changes are made with TCAs. ECG monitoring 
with SSRI treatment may be useful in high risk cases, 
though this is usually unnecessary.     
 Blood  dyscrasias 
  There are rare reports of blood dyscrasias with antide-
pressant administration. Case reports have included mian-
serin- or mirtazapine-induced neutropenia [132] and 
citalopram-induced thrombocytopenia [133]. Agranulo-
cytosis induced by newer antidepressants is much less 
common than that which was reported with tricyclic or 
tetracyclic antidepressants [8]. Monitoring of the full 
blood examination in patients treated with antidepressants 
may be prudent when rechallenging patients with a his-
tory of a blood dyscrasia. With mirtazapine and mian-
serin, one should be alert for emergent symptoms such as 
fever, sore throat, stomatitis or other signs of infections. 
If such symptoms occur, haematological investigations 
should be undertaken and the treatment stopped. Given 
the very low yield of screening for this very rare adverse 
event, routine haematological monitoring is not justiﬁ   ed.   
 Hepatotoxicity 
  Numerous antidepressants have been found to affect 
the liver. The MAOIs and the TCAs are associated with 
an appreciable though infrequent risk of hepatotoxicity 
[134]. However, changes in hepatic enzyme levels have 
rarely been reported for SSRIs and other newer antide-
pressants including paroxetine [135  –  137], sertraline 
[138,139], ﬂ   uoxetine [140,141], mianserin [142], mir-
tazapine [143,144], bupropion [145], trazodone [146,147], 
nefazodone [14], venlafaxine [146], duloxetine [148] and 
agomelatine [149]. Disentangling these rare reports from 
baseline-associated factors is difﬁ  cult.  Antidepressant-
induced hepatotoxicity is usually an idiosyncratic adverse 
drug reaction of low prevalence characterized by elevated 
ALT and sometimes by jaundice. The consequences of 
antidepressant-induced changes in hepatic function can 
range from asymptomatic changes [144] to fatal outcomes 
[145]. It is unclear whether the use of antidepressants may 
aggravate existing hepatic disease. Pre-existing hepatic 
disease may alter the metabolic clearance of some antide-
pressants and may necessitate dose adjustment [134]. 720    ANTIDEPRESSANT SAFETY GUIDELINES   
on osteoblast and osteoclast function. There are data 
indicating that, independent of treatment, people with 
depression have lower bone mineral density and a higher 
fracture risk, which is likely to be a compound result of 
lifestyle factors, disease state and iatrogenic treatment 
effects. These disease-related effects, combined with the 
effects on treatment, suggest that screening for bone min-
eral density should be considered in people on long-term 
SSRIs, and particularly in high risk groups such as the 
elderly, women and those with other risk factors such as 
fracture history, history of falls, low vitamin D, hypogo-
nadism, hyperparathyroidism, thyroid dysfunction, sys-
temic inﬂ   ammatory disorders, and corticosteroid use. 
Physical inactivity, alcohol use and smoking are shared 
lifestyle risk factors for both depression and low BMD.     
  Other adverse effects 
  Antidepressant treatment is commonly associated 
with milder adverse effects. The Antidepressant Side-
Effect Checklist itemizes 21 adverse events; nausea or 
vomiting, sexual dysfunction, increased appetite, 
decreased appetite, sweating, increased body tempera-
ture, weight gain, dry mouth, drowsiness, insomnia, 
blurred vision, headache, constipation, diarrhoea, prob-
lems with urination, palpitations, orthostatic dizziness, 
vertigo, tremor, disorientation, and yawning [9]. Such 
adverse effects are important causes of non-adherence 
to antidepressant treatment [9] and should therefore be 
routinely monitored.     
 Drug – drug  interactions 
  Monitoring should take into account that antidepres-
sants may interact with other medications and reduce the 
therapeutic effect or increase side-effects. Perhaps one of 
the most important differences between the newer anti-
depressants is their varying potential to cause drug  –  drug 
interactions through inhibition of cytochrome-P450 
(CYP) enzymes [170]. Fluvoxamine, a potent inhibitor 
of CYP1A2 and CYP2C19, is a particular cause for con-
cern with clinically relevant interactions reported with 
caffeine, clozapine, benzodiazepines, warfarin and other 
medications [170,171]. SSRIs such ﬂ  uoxetine and parox-
etine, which are potent inhibitors of CYP2D6, can also 
produce relevant interactions with other medications 
including beta-blockers, tricyclic antidepressants and 
antipsychotics such as perphenazine [172]. Special atten-
tion should be given to ﬂ   uoxetine because inhibitory 
effects can persist for up to ﬁ  ve weeks after discontinu-
ation. Sertraline, citalopram and escitalopram seem to 
have less interaction potential than the other SSRIs 
[170,173]. Duloxetine and bupropion are moderate inhib-
itors of CYP2D6, while venlafaxine, mirtazapine 
hyponatraemia have been reported [156]. Liu   et al .  [157] 
reported on 736 cases between 1980 and 1995 associated 
with ﬂ  uoxetine, ﬂ  uvoxamine, paroxetine and sertraline 
use. Hyponatraemia has also been reported for citalo-
pram [158], escitalopram [159], duloxetine [160], mir-
tazapine [161] and reboxetine [162]. It has been suggested 
that the risk may be greatest for patients who take ﬂ  uox-
etine compared to other antidepressants [154]. SSRIs can 
induce isovolemic hyponatraemia through a syndrome of 
inappropriate anti-diuretic hormone (SIADH) secretion 
[159]. Hyponatraemia can resolve with antidepressant 
discontinuation and reoccur with rechallenge [160]. 
Baseline screening of patients should include an assess-
ment of risk factors for antidepressant-induced hypona-
traemia including advanced age (    65 years) [157], 
previous history of antidepressant-induced hyponatrae-
mia [160], low body weight [155], thiazide use [163], 
and the use of other agents that may cause hyponatraemia 
such as carbamazepine [164]. Anecdotally, female gen-
der [163] may also be a risk factor. Most cases of hypona-
traemia occur within the ﬁ   rst 10 weeks of initiating 
antidepressant treatment, with 79% occurring in the ﬁ  rst 
3 weeks [154]. Regular monitoring of serum sodium in 
elderly patients has been recommended by some clini-
cians [154]. SIADH may also cause a worsening of 
depressive symptoms [154,159] and therefore should be 
sought and excluded. SIADH should be investigated if a 
person reports clinical deterioration, cognitive change or 
dizziness and fatigue after initiation of antidepressant 
treatment [159]. There is no current protocol for monitor-
ing serum sodium in patients being treated with antide-
pressants; however, monitoring after 3-4 weeks of 
treatment should occur in individuals who match the high 
risk proﬁ   le  [155].   
  Bone mineral density 
  There are recent data indicating that SSRIs may reduce 
bone mineral density [165]. Serotonin has a key signal-
ling role in bone cells and inﬂ  uences bone metabolism. 
Williams   et al  . showed a loss of 6.2% of bone mineral 
density (BMD) with SSRI treatment [166]. This magni-
tude of bone loss has the potential to lead to a 20% 
increased fracture risk. Bolton   et al  . described SSRI use 
in older adults being associated with an increased odds 
of osteoporotic fractures (OR      1.45), as for other mono-
amine antidepressants (OR        1.15), although the rela-
tionship was weaker [167]. These data are supported by 
a study showing that the risk of non-vertebral fracture for 
those over 55 years was two-fold for current users of 
SSRIs compared with non-users of antidepressants [168]. 
Preliminary data suggest intra-class differences [169], 
with citalopram seeming to have the lowest impact       S. DODD, G. S. MALHI, J. TILLER ET AL. 721
further research on risk, tolerability and safety of 
treatments. 
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